Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis

Blood Purif. 2022;51(2):189-192. doi: 10.1159/000513423. Epub 2021 Sep 9.

Abstract

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.

Keywords: Anti-erythropoietin antibody; Hemodialysis; Pure red cell aplasia; Roxadustat.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Erythropoietin* / therapeutic use
  • Glycine / analogs & derivatives
  • Humans
  • Isoquinolines
  • Male
  • Recombinant Proteins
  • Red-Cell Aplasia, Pure* / drug therapy
  • Red-Cell Aplasia, Pure* / etiology
  • Renal Dialysis / adverse effects

Substances

  • Isoquinolines
  • Recombinant Proteins
  • Erythropoietin
  • Glycine
  • roxadustat